MedTrace Logo

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01241331 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2012-10-01

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of formulation BLI1100 to its vehicle in the treatment of moderate-severe acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

BLI1100

BLI110 topical cream

DRUG

Vehicle cream

Vehicle topical cream

Sponsors & Collaborators

  • Braintree Laboratories

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01241331 on ClinicalTrials.gov